期刊文献+

5-氮杂脱氧胞苷和苯丁酸钠对卵巢癌细胞SKOV3的影响 被引量:2

Effects of 5-Aza-2'-deoxycytidine and sodium 4-phenylbutyrate on ovarian cancer cell line SKOV3
下载PDF
导出
摘要 目的观察5-氮杂脱氧胞苷(5-Aza-2'-CdR)和苯丁酸钠(SPB)对卵巢癌细胞SKOV3生长及侵袭能力的影响。方法应用相差显微镜观察SKOV3用5-Aza-2'-CdR和SPB处理前后细胞的形态变化;应用细胞生长曲线、四甲基偶氮唑蓝(MTT)比色法观察细胞生长的抑制作用;采用流式细胞术测定细胞周期分布的变化;用Transwell小室法检测药物处理前后细胞侵袭力的变化。结果 5-Aza-2'-CdR和SPB联用时,卵巢癌细胞SKOV3的核形态变化明显,细胞的生长速度明显减慢,细胞周期被阻滞在G0/G1期,S期细胞数减少;药物处理后SKOV3卵巢癌细胞的侵袭能力降低与对照组、单用药组相比,P<0.05。结论 5-Aza-2'-CdR和SPB联用时有明显的增效作用。 [Objective]To study the inducing and invasion ability effects of DNA methyhransferase inhibitor 5Aza-2'-deoxycytidine (5-Aza-2'-CdR) and histone deacetylase inhibitor sodium 4-phenylbutyrate (SPB) on ovarian cancer cell line SKOV3. [Methods]Ovarian cancer cell line SKOV3 was treated by 5-Aza-2′-deoxycytidines and sodium 4-phenylbutyrate, the cells morphosis were observed by phase contrast microscope. Cellular proliferation was determined by the cell growth curve and MTT assay. The cell cycle were analyzed by flow cytometry. The invasion ability of SKOV3 cells was tested by transwell chamber assay.[Results]Compared with the control and Single drug group, SKOV3 cell displayed differentiation tendency of morphology, such as decreased atypia and nucleus to cytoplasm ratio,the cell growth speed was significantly slowed down ,the cell cycle was arrested at G0/G1 phase and cell number in S phase was decreased after 5-Aza-2'-CdR combined with SPB treatment (P 0.05). The invasion ability of SKOV3 cell decreased after 5-Aza-2'-CdR combined with SPB treatment (P 0.05).[Conclusion]The combining DNA methyhransferase inhibitors with histone deacetylase inhibitors have an obvious synergistic effects of induction and invasive ability.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2010年第11期1634-1638,共5页 China Journal of Modern Medicine
基金 天津市自然科学基金(No:08JCYBJC08200)
关键词 5-氮杂脱氧胞苷 苯丁酸钠 卵巢癌 5-Aza-2'-deoxycytidine sodium 4-phenylbutyrate ovarian cancer
  • 相关文献

参考文献3

二级参考文献30

  • 1张松,孔维佳.死亡相关蛋白激酶基因启动子区过甲基化与喉癌的关系[J].中华肿瘤杂志,2004,26(8):469-471. 被引量:5
  • 2龚丽明,王忠明,林世杰,李鸿钧.巢式RT-PCR扩增CK20诊断大肠癌淋巴结微转移的初步研究[J].肿瘤防治杂志,2005,12(5):348-352. 被引量:4
  • 3涂洪谊,陈卫民.DNA甲基化转移酶抑制剂与胸苷酸合成酶抑制剂体外联合用药的抗肿瘤增效作用[J].生命科学研究,2005,9(4):366-370. 被引量:5
  • 4MASAYUKI S,MASASHI A.TOSHIHIKO T,et al Transmembrane 4 superfamily as a prognostic factor in pancereatic cancer[J].Int J.Cancer(Pred Oncol),1998,79:509-516.
  • 5SHINGO MIYAMOTO,AKIKO MARUYAMA.Loss of Motility-Related Protein 1 (MRP1/CD9) and integrin a3 Expression in Endometrial Cancers[J].Cancer,2001,92:542-548.
  • 6HEMLER ME,MANNION BA,BERDITCHEVSKI F.Association of TM4SF proteins with integrins:relevance to cancer[J].Biochim Biophys Acta,1996,1287:67.
  • 7CHENG-LONG HUANG,NOBUOKI KOHNO,EIJI OGAWA,et al.Correlation of Reduction in MRP-1/CD9 and KAI1/CD82 Expression with Recurrences in Breast Cancer Patients[J].American Journal of Pathology,1998,153:973-983.
  • 8MASAYUKI MIYAKE,MASARU KOYAMA,MASAHARU SENO,et al.Identification of the motility-related protein (MRP-1),recognized by monoclonal antibody M31-15,which inhibits cell motility[J].J Exp Med,1991,174:1347-1354.
  • 9RUBINSTEIN E,BENOIT P,BILLARD M,et al.Organization of the human CD9 gene[J].Immunogenetics,1993,37:193-198.
  • 10MAECKER HT,TODD SC,LEVY S.The tetraspanin superfamily:molecular facilitators[J].FASEB J,1997,11:428-442.

共引文献17

同被引文献25

  • 1Willmott L J, Monk B J. Cervical cancer therapy: current, future and anti-angiogensis targeted treatment[J]. Expert Rev Anticancer Ther, 2009, 9 (7) : 895 - 903.
  • 2Mani S, Herceg Z. DNA demethylating agents and epigenetic therapy of cancer[J]. Adv Genet, 2010, 70:327-340.
  • 3Vinken M, De-Rop E, Decrock E, et al. Epigenetic regulation of gap junctional intercellular communication: more than a way to keep cells quiet? [J]. Biochim Biophys Acta, 2009, 1795 (1) :53 -61.
  • 4Peixoto P, Lansiaux A. Histone-deacetylases inhibitors: from TSA to SAHA[J]. Bull Cancer, 2006, 93(1): 27-36.
  • 5Bartolini G, Ammar K, Mantovani B, et al. Retinoids and cancer: antitumor effect of ATRA and of a new derivative of retinoie acid, IIF, on colon carcinoma cell lines CaCo-2 and HT-29 [ J]. Anticancer Res,2004,24 (3 a) : 1779 - 1783.
  • 6BianFL, Jia LX, Yu W, et al. Self-assembled micelles of N- phthaloylchitosan-g-polyvinylpyrrolidone for drug delivery[J]. Carbohydrate Polymers, 2009, 76(3) : 454 -459.
  • 7Huang S, Laoukili J, Epping M T, et al. ZNF423 is critically Required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome [ J ].Cancer Cell, 2009, 15 (4) : 328 - 340.
  • 8Deimling S J, Drysdale T A. Retinoic acid regulates anterior-posterior patterning within the lateral plate mesoderm of Xenopus [ J ]. Mech Dev, 2009, 126(10) :913 -923.
  • 9Carducci M A, Gilbert J, Bowling M K, et al. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule[J]. Clin Cancer Res, 2001, 7(10) :3047 -3055.
  • 10Monneret C. Histone deacetylase inhibitors [ J]. Eur J Med Chem, 2005, 40(1): 1-13.

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部